7.40
-0.14(-1.86%)
Currency In USD
Address
Babraham Research Campus
Cambridge, CB22 3AT
United Kingdom of Great Britain and Northern Ireland
Phone
44 1223 261 503
Sector
Healthcare
Industry
Biotechnology
Employees
305
First IPO Date
May 23, 2019
| Name | Title | Pay | Year Born |
| Dr. Kevin Lee M.B.A., Ph.D. | Chief Executive Officer & Executive Director | 1.5M | 1968 |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D. | Co-Founder & Non-Executive Director | 66,917 | 1951 |
| Prof. Michael Charles-Ferguson Hannay | Chief Product & Supply Chain Officer | 698,383 | 1966 |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer | 881,008 | 1969 |
| Mr. Alistair Milnes | Chief Operating Officer | 909,050 | 1974 |
| Ms. Alethia Rene Young | Chief Financial Officer | 948,767 | 1979 |
| Dr. Christian Heinis | Scientific Founder | 0 | N/A |
| Ms. Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications | 0 | N/A |
| Mr. Travis Thompson | Senior Vice President, Chief Accounting Officer & Principal Accounting Officer | 0 | N/A |
| Mr. Zafar Qadir | Chief Legal Officer & General Counsel | 0 | N/A |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.